A Phase I, Multi-centre, Double-blind, Placebo-controlled Parallel Group Study to Assess the pharmacoMRI Effects of AZD6765 in Male and Female Patients Fulfilling the Criteria for Major Depressive Disorder.

Trial Profile

A Phase I, Multi-centre, Double-blind, Placebo-controlled Parallel Group Study to Assess the pharmacoMRI Effects of AZD6765 in Male and Female Patients Fulfilling the Criteria for Major Depressive Disorder.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2012

At a glance

  • Drugs Lanicemine (Primary) ; Ketamine
  • Indications Major depressive disorder
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 13 Oct 2012 Results presented at the 25th Annual Congress of the European College of Neuropsychopharmacology.
    • 25 Jul 2012 New source identified and integrated (EudraCT2009-013110-27: European Clinical Trials Database).
    • 07 Jun 2012 Results reported at the 28th International Congress of Cellegium Internationale Neuro-Psychopharmacologicum].
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top